Download MendeleyOptimization and In Vivo Characterization of a Series of Cbl‐b Inactive-State Inhibitors.
Lambrecht, M.J., Liang, J., Ung, P.M., Huestis, M.P., Zhu, B.Y., Barton, L.M., Castanedo, G.M., Zbieg, J.R., Larouche-Gauthier, R., Jakalian, A., Leclerc, J.P., Yadav, A., Haghshenas, P., Aubert-Nicol, S., Ismaili, H., Zhao, L., Leblanc, M., Wang, J., Wang, S., Wang, Q., Garner, T., Tan, S., Prangley, M., Broccatelli, F., Pang, J., Murray, J., Yu, C., Hsu, P., Rutz, S., Kakiuchi-Kiyota, S., Ishizuka, I., Leung, D.H., Kou, P., Bao, L., Wang, X.(2026) ACS Med Chem Lett 17: 1253-1257
- PubMed: 42305211 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acsmedchemlett.6c00103
- Primary Citation Related Structures:
10ZJ - PubMed Abstract:
Casitas B-lineage lymphoma-b (Cbl-b), an E3 ubiquitin ligase, is a key negative regulator of immune function, and its inhibition is a promising strategy for cancer immunotherapy. Here, we show the optimization of a series of inactive-state Cbl-b inhibitors to improve their potency and pharmacokinetic properties. Through systematic modification of a benzylic amine and a linker region, compound 16 was identified, which demonstrates a favorable balance of biochemical potency, cellular activity, and in vitro ADME properties. Despite exhibiting high IV clearance in vivo , compound 16 achieved oral exposures sufficient to demonstrate significant tumor growth inhibition in a murine CT26 colon-cancer model.
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Organizational Affiliation:
